Stroke biomarkers: Can they help us to guide stroke thrombolysis?

Drug News and Perspectives

Volumn 19, Issue 9, 2006, Pages 523-532

  Montaner, Joan ^a  

^a HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALTEPLASE; BATIMASTAT; BIOLOGICAL MARKER; C REACTIVE PROTEIN; COLLAGENASE 3; DISUFENTON SODIUM; FIBRONECTIN; GELATINASE B; GELATINASE INHIBITOR; GLIAL FIBRILLARY ACIDIC PROTEIN; HOMOCYSTEINE; LIPOPROTEIN A; MONOCYTE CHEMOTACTIC PROTEIN 1; NEUROTROPHIC FACTOR; PLACEBO; PLASMINOGEN ACTIVATOR INHIBITOR 1; PROTEIN S100B; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

BLOOD BRAIN BARRIER; BLOOD CLOT LYSIS; BLOOD VESSEL OCCLUSION; BRAIN EDEMA; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CELL DEATH; CEREBROVASCULAR ACCIDENT; CEREBROVASCULAR DISEASE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DRUG MECHANISM; FIBRINOLYTIC THERAPY; GENOMICS; HUMAN; MONOTHERAPY; MORTALITY; NONHUMAN; OXIDATIVE STRESS; PATIENT REFERRAL; PHARMACOGENOMICS; PROTEIN EXPRESSION; PROTEOMICS; REPERFUSION INJURY; REVIEW; STROKE; VEIN OCCLUSION;

ANIMALS; BIOLOGICAL MARKERS; CEREBROVASCULAR ACCIDENT; FIBRINOLYTIC AGENTS; HUMANS; MATRIX METALLOPROTEINASES; OXIDATIVE STRESS; PHARMACOGENETICS; THROMBOLYTIC THERAPY; TISSUE PLASMINOGEN ACTIVATOR;

EID: 33846522259     PISSN: 02140934     EISSN: None     Source Type: Journal    
DOI: 10.1358/dnp.2006.19.9.1050422     Document Type: Review

References (93)

1. Di Napoli, M., Schwaninger, M., Cappelli, R. et al. Evaluation of C-reactive protein measurement for assessing the risk and prognosis in ischemic stroke: a statement for health care professionals from the CRP Pooling Project members. Stroke 2005, 36: 1316-29.
2. Oei, H.H., van der Meer, I.M., Hofman, A. et al. Lipoprotein- associated phospholipase A2 activity is associated with risk of coronary heart disease and ischemic stroke: The Rotterdam Study. Circulation 2005, 111: 570-5.
3. Reynolds, M.A., Kirchick, H.J., Dahlen, J.R. et al. Early biomarkers of stroke. Clin Chem 2003, 49: 1733-9.
4. Lynch, J.R., Blessing, R., White, W.D., Grocott, H.P., Newman, M.F. and Laskowitz, D.T. Novel diagnostic test for acute stroke. Stroke 2004, 35: 57-63.
5. Foerch, C., Curdt, I., Yan, B. et al. Serum glial fibrillary acidic protein as a biomarker for intracerebral haemorrhage in patients with acute stroke. J Neurol Neurosurg Psychiatry 2006, 77: 181-4.
6. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med 1995, 333: 1581-7.
7. Heuschmann, P.U., Berger, K., Misselwitz, B. et al. Frequency of thrombolytic therapy in patients with acute ischemic stroke and the risk of in-hospital mortality: The German Stroke Registers Study Group. Stroke 2003, 34: 1106-13.
8. Rubiera, M., Alvarez-Sabin, J., Ribo, M. et al. Predictors of early arterial reocclusion after tissue plasminogen activator-induced recanalization in acute ischemic stroke. Stroke 2005, 36: 1452-6.
9. Tanne, D., Kasner, S.E., Demchuk, A.M. et al. Markers of increased risk of intracerebral hemorrhage after intravenous recombinant tissue plasminogen activator therapy for acute ischemic stroke in clinical practice: The Multicenter rt-PA Stroke Survey. Circulation 2002, 105: 1679-85.
10. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-PA therapy for ischemic stroke. Stroke 1997, 28: 2109-18.
11. Larrue, V., von Kummer, R., del Zoppo, G. and Bluhmki, E. Hemorrhagic transformation in acute ischemic stroke. Potential contributing factors in the European Cooperative Acute Stroke Study. Stroke 1997, 28: 957-60.
12. Kidwell, C.S., Saver, J.L., Villablanca, J.P. et al. Magnetic resonance imaging detection of microbleeds before thrombolysis: An emerging application. Stroke 2002, 33: 95-98.
13. Alexandrov, A.V., Black, S.E., Ehrlich, L.E., Caldwell, C.B. and Norris, J.W. Predictors of hemorrhagic transformation occurring spontaneously and on anticoagulants in patients with acute ischemic stroke. Stroke 1997, 28: 1198-202.
14. Wang, X., Tsuji, K., Lee, S.R. et al. Mechanisms of hemorrhagic transformation after tissue plasminogen activator reperfusion therapy for ischemic stroke. Stroke 2004, 35: 2726-30.
15. Hacke, W., Donnan, G, Fieschi, C. et al. Association of outcome with early stroke treatment: Pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet 2004, 363: 768-74.
16. Albers, G.W., Bates, V.E., Clark, W.M., Bell, R., Verro, P. and Hamilton, S.A. Intravenous tissue-type plasminogen activator for treatment of acute stroke: The Standard Treatment with Alteplase to Reverse Stroke (STARS) study. JAMA 2000, 283: 1145-50.
17. Katzan, I.L., Furlan, A.J., Lloyd, L.E. et al. Use of tissue-type plasminogen activator for acute ischemic stroke: The Cleveland area experience. JAMA 2000, 283: 1151-8.
18. Hill, M.D. and Buchan, A.M. Methodology for the Canadian Activase for Stroke Effectiveness Study (CASES). CASES Investigators. Can J Neurol Sci 2001, 28: 232-8.
19. Petty, M.A. and Lo, E.H. Junctional complexes of the blood-brain barrier: Permeability changes in neuroinflammation. Prog Neurobiol 2002, 68: 311-23.
20. Lo, E.H., Broderick, J.P. and Moskowitz, M.A. tPA and proteolysis in the neurovascular unit. Stroke 2004, 35: 354-6.
21. Nicole, O., Docagne, F., Ali, C. et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001, 7: 59-64.
22. Yang, Y., Li, Q., Yang, T., Hussain, M. and Shuaib, A. Reduced brain infarct volume and improved neurological outcome by inhibition of the NR2B subunit of NMDA recep tors by using CP101,606-27 alone and in combination with rt-PA in a thromboembolic stroke model in rats. J Neurosurg 2003, 98: 397-403.
23. Lo, E.H., Dalkara, T. and Moskowitz, M.A. Mechanisms, challenges and opportunities in stroke. Nat Rev Neurosci 2003, 4: 399-415.
24. Gasche, Y., Copin, J.C., Sugawara, T., Fujimura, M. and Chan, P.H. Matrix metalloproteinase inhibition prevents oxidative stress-associated blood-brain barrier disruption after transient focal cerebral ischemia. J Cereb Blood Flow Metab 2001. 21: 1393-400.
25. Hamann, GF, Okada, Y. and del Zoppo, G.J. Hemorrhagic transformation and microvascular integrity during focal cerebral schemia/reperfusion. J Cereb Blood Flow Metab 1996, 16: 1373-8.
26. Yepes, M., Sandkvist, M., Moore, E.G., Bugge, T.H., Strickland, D.K. and Lawrence, D.A. Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein. J Clin Invest 2003, 112: 1533-40.
27. Matrisian, L.M. Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 1990, 6: 121-5.
28. Mun-Bryce, S. and Rosenberg, G.A. Matrix metalloproteinases in cerebrovascular disease. J Cerebral Blood Flow Metab 1998, 18: 1163-72.
29. Rosenberg, G.A., Mun-Bryce, S., Wesley, M. and Kornfeld, M. Collagenase-induced intracerebral hemorrhage in the rat. Stroke 1990, 21: 801-7.
30. Heo, J.H., Lucero, J., Abumiya, T., Koziol, J.A., Copeland, B.R. and del Zoppo, G.J. Matrix metalloproteinases increase very early during experimental focal cerebral ischemia. J Cereb Blood Flow Metab 1999, 19: 624-33.
31. Murphy, G, Atkinson, S., Ward, R., Gavrilovic, J. and Reynolds, J.J. The role of plasminogen activators in the regulation of connective tissue metalloproteinases. Ann NY Acad Sci 1992, 667: 1-12.
32. Asahi, M., Wang, X., Mori, T. et al. Effects of matrix metalloproteinase-9 gene knockout on the proteolysis of blood-brain barrier and white matter components after cerebral ischemia. J Neurosci 2001, 21: 7724-32.
33. Rosenberg, G.A., Estrada, E.Y. and Dencoff, J.E. Matrix metalloproteinases and TIMPs are associated with blood-brain barrier opening after reperfusion in rat brain. Stroke 1998, 29: 2189-95.
34. Lapchak, P.A., Chapman, D.F. and Zivin, J.A. Metalloproteinase inhibition reduces thrombolytic (tissue plasminogen activator)-induced hemorrhage after thromboembolic stroke. Stroke 2000, 31: 3034-40.
35. Tsuji, K., Auki, T., Tejima, E. et al. Tissue plasminogen activator promotes matrix metalloproteinase-9 upregulation after focal cerebral ischemia. Stroke 2005, 36: 1954-9.
36. Montaner, J., Molina, C.A., Arenillas, J.F. et al. Proteolytic modifications on the metalloproteinase system (MMP-9-Laminin-TIMP-1) induced by t-PA treatment for acute cerebral ischemia in humans. Stroke 2004, 35: 339.
37. Kano, T., Katayama, Y., Tejima, E. and Lo, E.H. Hemorrhagic transformation after fibrinolytic therapy with tissue plasminogen activator in a rat thromboembolic model of stroke. Brain Res 2000, 854: 245-8.
38. Justicia, C., Panes, J., Sole, S. et al. Neutrophil infiltration increases matrix metalloproteinase-9 in the ischemic brain after occlusion/reperfusion of the middle cerebral artery in rats. J Cereb Blood Flow Metab 2003, 23: 1430-40.
39. Wang, X., Lee, S.R., Arai, K. et al. Lipoprotein receptor-mediated induction of matrix metalloproteinase by tissue plasminogen activator. Nat Med 2003, 9: 1313-7.
40. Morita-Fujimura, Y., Fujimura, M., Gasche, Y., Copin, J.C. and Chan, P.H. Overexpression of copper and zinc superoxide dismutase in transgenic mice prevents the induction and activation of matrix metalloproteinases after cold injury-induced brain trauma. J Cereb Blood Flow Metab 2000, 20: 30-138.
41. Maier, C.M., Hsieh, L., Yu, F., Bracci, P. and Chan, P.H. Matrix metalloproteinase-9 and myeloperoxidase expression: Quantitative analysis by antigen immunohistochemistry in a model of transient focal cerebral ischemia. Stroke 2004, 35: 1169-74.
42. Gu, Z., Kaul, M., Yan, B. et al. S-nitrosylation of matrix metalloproteinases: Signaling pathway to neuronal cell death. Science 2002, 297: 1186-90.
43. Lijnen, H.R. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001, 86: 324-33.
44. Aoki, T., Sumii, T., Mori, T., Wang, X. and Lo, E.H. Blood-brain barrier disruption and matrix metalloproteinase-9 expression during reperfusion injury: mechanical versus embolic focal ischemia in spontaneously hypertensive rats. Stroke 2002, 33: 2711-7.
45. Versnick, E.J., Do, H.M., Albers, G.W., Tong, D.C. and Marks, M.P. Mechanical thrombectomy for acute stroke. AJNR Am J Neuroradiol 2005, 26: 875-9.
46. Zhao, B.Q., Ikeda, Y., Ihara, H. et al. Essential role of endogenous tissue plasminogen activator through matrix metalloproteinase 9 induction and expression on heparin-produced cerebral hemorrhage after cerebral ischemia in mice. Blood 2004, 103: 2610-6.
47. Sumii, T. and Lo, E.H. Involvement of matrix metalloproteinase in thrombolysis-associated hemorrhagic transformation after embolic focal ischemia in rats. Stroke 2002, 33: 831-6.
48. Gu, Z., Cui, J., Brown, S. et al. A highly specific inhibitor of matrix metalloproteinase-9 rescues laminin from proteolysis and neurons from apoptosis in transient focal cerebral ischemia. J Neurosci 2005, 25: 6401-8.
49. Montaner, J., Alvarez-Sabín, J., Molina, C. et al. Matrix metalloproteinase expression after human cardioembolic stroke. Temporal profile and relation to neurological impairment. Stroke 2001, 32: 1759-66.
50. Montaner, J., Alvarez-Sabin, J., Molina, C. et al. Matrix metalloproteinase (MMP-9) expression is related to hemorrhagic transformation after cardioembolic stroke. Stroke 2001, 32: 2762-7.
51. Castellanos, M., Leira, R., Serena, J. et al. Plasma metalloproteinase-9 concentration predicts hemorrhagic transformation in acute ischemic stroke. Stroke 2003, 34: 40-6.
52. Montaner, J., Molina, C.A., Monasterio, J. et al. Matrix metalloproteinase-9 pretreatment level predicts intracranial hemorrhagic complications after thrombolysis in human stroke. Circulation 2003, 107: 598-603.
53. Demchuk, A.M., Morgenstern, L.B., Krieger, D.W. et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke 1999, 30: 34-9.
54. Uemura, S., Matsushita, H., Li, W. et al. Diabetes mellitus enhances vascular matrix metalloproteinase activity: role of oxidative stress. Circ Res 2001, 88: 1291-8.
55. Massengale, J.L., Gasche, Y. and Chan, P.H. Carbohydrate source influences gelatinase production by mouse astrocytes in vitro. Glia 2002, 38: 240-5.
56. Rosell, A., Alvarez-Sabin, J., Arenillas, J.F. et al. A matrix metalloproteinase protein array reveals a strong relation between MMP-9 and MMP-13 with diffusion-weighted image lesion increase in human stroke. Stroke 2005, 36: 1415-20.
57. Hynes, R.O. Fibronectins. Sci Am 1986, 254: 42-51.
58. Peters, J.H., Sporn, L.A., Ginsberg, M.H. and Wagner, D.D. Human endothelial cells synthesize, process, and secrete fibronectin molecules bearing an alternatively spliced type II homology (EDI). Blood 1990, 75: 1801-8.
59. Peters, J.H., Maunder, R.J., Woolf, A.D., Cochrane, G.H. and Ginsberg, M.H. Elevated plasma levels of ED1+ ("cellular") fibronectin in patients with vascular injury. J Lab Clin Med 1989, 113: 586-97.
60. Kanters, S.D., Banga, J.D., Algra, A., Frijns, R.C., Beutler, J.J. and Fijnheer, R. Plasma levels of cellular fibronectin in diabetes. Diabetes Care 2000, 24: 323-7.
61. Castellanos, M., Leira, R., Serena, J. et al. Plasma cellular-fibronectin concentration predicts hemorrhagic transformation after thrombolytic therapy in acute ischemic stroke. Stroke 2004, 35: 1671-6.
62. Chan, P.H. Reactive oxygen radicals in signaling and damage in the ischemic brain. J Cereb Blood Flow Metab 2001, 21: 2-14.
63. Asahi, M., Asahi, K., Wang, X. and Lo, E.H. Reduction of tissue plasminogen activator-induced hemorrhage and brain injury by free radical spin trapping alter embolia focal cerebral ischemia in rats. J Cereb Blood Flow Metab 2000, 20: 452-7.
64. Lapchak, P.A., Chapman, D.F. and Zivin, J.A. Pharmacological effects of the spin trap agents N-t-butyl-phenylnitrone (PBN) and 2,2,6, 6-tetramethylpiperidine-N-oxyl (TEMPO) in a rabbit thromboembolic stroke model: Combination studies with the thrombolytic tissue plasminogen activator. Stroke 2001, 32: 147-53.
65. Lees, K.R., Zivin, J.A., Ashwood, T. et al. NXY-059 for acute ischemic stroke. N Engl J Med 2006, 354: 588-600.
66. Collet, J.P., Montalescot, G., Vicaut, E. et al. Acute release of plasminogen activator inhibitor-1 in ST-segment elevation myocardial infarction predicts mortality. Circulation 2003, 108: 391-4.
67. Montaner, J., Ribo, M., Monasterio, J., Molina, C.A. and Alvarez-Sabin, J. Thrombin-activable fibrinolysis inhibitor levels in the acute phase of ischemic stroke. Stroke 2003, 34: 1038-40.
68. Ribo, M., Montaner, J., Molina, C.A. et al. Admission fibrinolytic profile is associated with symptomatic hemorrhagic transformation in stroke patients treated with tissue plasminogen activator. Stroke 2004, 35: 2123-7.
69. Cocho, D., Borrell, M., Marti-Fabregas, J. et al. Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with Tissue Plasminogen Activator. Stroke 2006, 37: 996-9.
70. Nagy, Z., Kolev, K., Csonka, E., Vastag, M. and Machovich, R. Perturbation of the integrity of the blood-brain barrier by fibrinolytic enzymes. Blood Coagul Fibrinolysis 1998, 9: 471-8.
71. Trouillas, P., Derex, L., Philippeau, F. et al. Early fibrinogen degradation coagulopathy is predictive of parenchymal hematomas in cerebral rt-PA thrombolysis: A study of 157 cases. Stroke 2004, 35: 1323-8.
72. Ribo, M., Montaner, J., Molina, C.A., Arenillas, J.F., Santamarina, E. and Alvarez-Sabin, J. Admission fibrinolytic profile predicts clot lysis resistance in stroke patients treated with tissue plasminogen activator. Thromb Haemost 2004, 91: 1146-51.
73. Marti-Fabregas, J., Borrell, M., Cocho, D. et al. Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA. Neurology 2005, 65: 366-70.
74. Foerch, C., du Mesnil de Rochemont, R., Singer, O. et al. S100B as a surrogate marker for successful clot lysis in hyperacute middle cerebral artery occlusion. J Neurol Neurosurg Psychiatry 2003, 74: 322-5.
75. Heo, J.H., Kim, S.H., Lee, K.Y., Kim, E.H., Chu, C.K. and Nam, J.M. Increase in plasma matrix metalloproteinase-9 in acute stroke patients with thrombolysis failure. Stroke 2003, 34: 48-50.
76. Vila, N., Castillo, J., Dávalos, A. and Chamorro, A. Proinflammatory cytokines and early neurological worsening in ischemic stroke. Stroke 2000, 31: 2325-9.
77. Fassbender, K., Rossol, S., Kammer, T. et al. Proinflammatory cytokines in serum of patients with acute cerebral ischemia: Kinetics of secretion and relation to the extent of brain damage and outcome disease. J Neurol Sci 1994, 122: 135-9.
78. Montaner, J., Fernandez-Cadenas, I., Molina, C.A. et al. Post-stroke C-reactive protein is a powerful prognostic tool among candidates for thrombolysis. Stroke 2006, 37: 1205-10.
79. Danenberg, H.D., Szalai, A.J., Swaminathan, R.V. et al. Increased thrombosis after arterial injury in human C-reactive protein-transgenic mice. Circulation 2003, 108: 512-5.
80. Gorman, M.J., Tanne, D. and Lewandowski, C.A. Centenarian stroke treated with tissue-type plasminogen activator. Cerebrovasc Dis 2002, 13: 285-7.
81. Foerch, C., Otto, B., Singer, O.C. et al. Serum S100B predicts a malignant course of infarction in patients with acute middle cerebral artery occlusion. Stroke 2004, 35: 2160-4.
82. Serena, J., Blanco, M., Castellanos, M. et al. The prediction of malignant cerebral infarction by molecular brain barrier disruption markers. Stroke 2005, 36: 1921-6.
83. Horstmann, S., Kalb, P., Koziol, J., Gardner, H. and Wagner, S. Profiles of matrix metalloproteinases, their inhibitors, and laminin in stroke patients. Influence of different therapies. Stroke 2003, 34: 2165-72.
84. Wunderlich, M.T., Lins, H., Skalej, M., Wallesch, C.W. and Goertler, M. Neuronspecific enolase and tau protein as neurobiochemical markers of neuronal damage are related to early clinical course and long-term outcome in acute ischemic stroke. Clin Neurol Neurosurg 2006, 108: 558-63. [Epub 2006 Feb 2].
85. Wunderlich, M.T., Hanhoff, T., Goertler, M. et al. Release of brain-type and heart-type fatty acid-binding proteins in serum after acute ischaemic stroke. J Neurol 2005, 252: 718-24.
86. Allard, L., Burkhard, P.R., Lescuyer, P. et al. PARK7 and nucleoside diphosphate kinase A as plasma markers for the early diagnosis of stroke. Clin Chem 2005, 51: 2043-51.
87. Jauch, E.C., Ross, G.F., Beiler, S., Beiler, C., Choudhri, T. and Wagner, K.R. Plasma biomarkers distinguish acute ischemic stroke patients at risk to develop intracerebral hemorrhage after thrombolytic therapy. Stroke 2006, 37: 635.
88. Tang, Y., Xu, H., Du, X. et al. Gene expression in blood changes rapidly in neutrophils and monocytes after ischemic stroke in humans: A microarray study. J Cereb Blood Flow Metab 2006, 26: 1089-102. [Epub 2006 Jan 4].
89. Marin, F., Roldan, V. Gonzalez-Conejero, R. and Corral, J. Pharmacogenetics in cardiovascular antithrombotic therapy. Curr Med Chem Cardiovasc Hematol Agents 2005, 3: 357-64.
90. Broderick, J., Lu, M., Jackson, C. et al. Apolipoprotein E phenotype and the efficacy of intravenous tissue plasminogen activator in acute ischemic stroke. Ann Neurol 2001, 49: 736-44.
91. Fernández-Cadenas, I., Alvarez-Sabín, J., Molina, C.A. et al. Influencia del genotipo del ApoE sobre la eficacia y seguridad del tratamiento trombolítico en el ictus isquémico. Neurologia 2006, 21: 176-80.
92. Montaner, J., Fernandez-Cadenas, I., Molina, C.A. et al. Safety profile of tissue plasminogen activator treatment among stroke patients carrying a common polymorphism (C-1562T) in the promoter region of the matrix metalloproteinase-9 gene. Stroke 2003, 34: 2851-5.
93. Fernández-Cadenas, I., Molina, C.A., Alvarez-Sabín, J. et al. ACE gene polymorphisms influence t-PA-induced brain vessel reopening following ischemic stroke. Neuroscience Letters 2006, 398: 167-71.